IceCure Medical Ltd - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
ICCM Nasdaq 3840 www.icecure-medical.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for IceCure Medical Ltd

IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement - Mar 26th, 2026 6:00 am
IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates - Mar 25th, 2026 6:30 am
IceCure Appoints Meir Peleg as Chief Financial Officer - Mar 24th, 2026 6:30 am
Icecure Medical Ltd (ICCM) Q4 2025 Earnings Call Highlights: Record Sales and Strategic U.S. ... - Mar 20th, 2026 7:00 pm
IceCure Medical (ICCM) Q4 2025 Earnings Transcript - Mar 17th, 2026 10:58 am
IceCure Medical Ltd Q4 2025 Earnings Call Summary - Mar 17th, 2026 10:40 am
IceCure Reports 2025 Full Year Financial & Operational Results - Mar 17th, 2026 6:30 am
What To Expect From Icecure Medical Ltd (ICCM) Q4 2025 Earnings - Mar 16th, 2026 7:20 am
U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer - Mar 11th, 2026 6:30 am
IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026 - Mar 10th, 2026 6:30 am
American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer - Mar 9th, 2026 6:30 am
IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas - Mar 2nd, 2026 6:30 am
Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board - Feb 27th, 2026 5:00 am
IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026 - Feb 23rd, 2026 6:30 am
IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation - Feb 19th, 2026 6:30 am
IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense® - Feb 11th, 2026 6:30 am
IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved - Feb 9th, 2026 2:30 pm
IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer - Jan 28th, 2026 6:30 am
When Will IceCure Medical Ltd (NASDAQ:ICCM) Turn A Profit? - Jan 15th, 2026 4:05 am
IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales - Jan 12th, 2026 6:30 am